Organon Balance Sheet Health
Financial Health criteria checks 1/6
Organon has a total shareholder equity of $493.0M and total debt of $8.7B, which brings its debt-to-equity ratio to 1774.6%. Its total assets and total liabilities are $12.8B and $12.3B respectively. Organon's EBIT is $1.5B making its interest coverage ratio 2.9. It has cash and short-term investments of $763.0M.
Key information
1,774.6%
Debt to equity ratio
US$8.75b
Debt
| Interest coverage ratio | 2.9x |
| Cash | US$763.00m |
| Equity | US$493.00m |
| Total liabilities | US$12.26b |
| Total assets | US$12.75b |
Recent financial health updates
Recent updates
Earnings Working Against Organon & Co.'s (NYSE:OGN) Share Price
Dec 13
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade)
Nov 13The Organon & Co. (NYSE:OGN) Third-Quarter Results Are Out And Analysts Have Published New Forecasts
Nov 04Roivant's Sale Of Dermavant To Organon: A Strategic Win-Win In Atopic Dermatitis
Sep 19These 4 Measures Indicate That Organon (NYSE:OGN) Is Using Debt In A Risky Way
Sep 13Organon & Co.: Cheap With Caveats
Aug 22Organon (NYSE:OGN) Will Pay A Dividend Of $0.28
Aug 09Insufficient Growth At Organon & Co. (NYSE:OGN) Hampers Share Price
Aug 07Organon: Upcoming Q2 Earnings Can Sustain Upward Momentum
Jul 30Organon & Co.'s (NYSE:OGN) CEO Might Not Expect Shareholders To Be So Generous This Year
May 29Organon's (NYSE:OGN) Solid Profits Have Weak Fundamentals
May 10Four Reasons Why Organon Stock Is A Good Buy
May 07Little Excitement Around Organon & Co.'s (NYSE:OGN) Earnings
Apr 21Organon Stock Is Still Worth A Look
Feb 24Organon (NYSE:OGN) Is Due To Pay A Dividend Of $0.28
Feb 19Organon Q4 And Full Year 2023 Earnings Review - Positive Updates At Last
Feb 16Organon: What I'm Looking For In This 8% Yield In 2024
Jan 03High Risk, High Reward: Why 8.5%-Yielding Organon Could Be Up To 90% Undervalued
Dec 19Organon: It's Darkest Before The Dawn
Nov 30Organon: Poor Q3 Earnings Make Bear Case, But Dividend Is Saving Grace
Nov 07Organon (NYSE:OGN) Has Affirmed Its Dividend Of $0.28
Nov 05Organon: The Federal Reserve Black Swan (Rating Upgrade)
Oct 046% Yield And Significantly Undervalued: A Closer Look At Organon
Sep 10Organon Q2 2023 Earnings Review: Incremental Growth With A Slather Of Risk
Aug 10Organon & Co.: A Tough Spot To Be In Right Now
Jul 16Organon goes ex-dividend tomorrow
Feb 23Organon & Co. (NYSE:OGN) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Feb 19Is There Anything Organic Or Interesting About Organon?
Feb 07Organon goes ex-dividend tomorrow
Nov 09Organon's (NYSE:OGN) Dividend Will Be $0.28
Nov 08Financial Position Analysis
Short Term Liabilities: OGN's short term assets ($4.8B) exceed its short term liabilities ($2.8B).
Long Term Liabilities: OGN's short term assets ($4.8B) do not cover its long term liabilities ($9.5B).
Debt to Equity History and Analysis
Debt Level: OGN's net debt to equity ratio (1619.9%) is considered high.
Reducing Debt: OGN's debt to equity ratio has increased from 2.6% to 1774.6% over the past 5 years.
Debt Coverage: OGN's debt is not well covered by operating cash flow (10.8%).
Interest Coverage: OGN's interest payments on its debt are not well covered by EBIT (2.9x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:20 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Organon & Co. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Balaji Prasad | Barclays |
| Balaji Prasad | Barclays |
| Navann Ty Dietschi | BNP Paribas Exane |